Literature DB >> 23900358

Lipid-lowering agents in chronic kidney disease: do fibrates have a role?

Yuli Huang, Yunzhao Hu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23900358     DOI： 10.1038/nrcardio.2013.15-c1

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  12 in total

Review 1.  Clinical assessment and management of dyslipidemia in patients with chronic kidney disease.

Authors:  Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-06-22       Impact factor: 2.801

2.  Do fibrates truly preserve kidney function?

Authors:  Suneel M Udani; George L Bakris
Journal:  Nat Rev Endocrinol       Date:  2011-02-08       Impact factor: 43.330

3.  Fibrates and cardiorenal outcomes.

Authors:  Peter A McCullough; Michael J Di Loreto
Journal:  J Am Coll Cardiol       Date:  2012-10-17       Impact factor: 24.094

4.  Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants.

Authors:  Marcin Barylski; Shekoufeh Nikfar; Dimitri P Mikhailidis; Peter P Toth; Pooneh Salari; Kausik K Ray; Michael J Pencina; Manfredi Rizzo; Jacek Rysz; Mohammad Abdollahi; Stephen J Nicholls; Maciej Banach
Journal:  Pharmacol Res       Date:  2013-03-28       Impact factor: 7.658

Review 5.  Management of cardiovascular disease in patients with kidney disease.

Authors:  Mark R Kahn; Michael J Robbins; Michael C Kim; Valentin Fuster
Journal:  Nat Rev Cardiol       Date:  2013-02-19       Impact factor: 32.419

Review 6.  Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis.

Authors:  Ashish Upadhyay; Amy Earley; Jenny L Lamont; Shana Haynes; Christoph Wanner; Ethan M Balk
Journal:  Ann Intern Med       Date:  2012-08-21       Impact factor: 25.391

Review 7.  Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis.

Authors:  Suetonia C Palmer; Jonathan C Craig; Sankar D Navaneethan; Marcello Tonelli; Fabio Pellegrini; Giovanni F M Strippoli
Journal:  Ann Intern Med       Date:  2012-08-21       Impact factor: 25.391

Review 8.  Effects of fibrates in kidney disease: a systematic review and meta-analysis.

Authors:  Min Jun; Bin Zhu; Marcello Tonelli; Meg J Jardine; Anushka Patel; Bruce Neal; Thaminda Liyanage; Anthony Keech; Alan Cass; Vlado Perkovic
Journal:  J Am Coll Cardiol       Date:  2012-10-17       Impact factor: 24.094

9.  Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.

Authors:  Ru-Dee Ting; Anthony C Keech; Paul L Drury; Mark W Donoghoe; John Hedley; Alicia J Jenkins; Timothy M E Davis; Seppo Lehto; David Celermajer; R John Simes; Kushwin Rajamani; Kim Stanton
Journal:  Diabetes Care       Date:  2011-12-30       Impact factor: 19.112

10.  Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants.

Authors:  Josyf C Mychaleckyj; Timothy Craven; Uma Nayak; John Buse; John R Crouse; Marshall Elam; Kent Kirchner; Daniel Lorber; Santica Marcovina; William Sivitz; Joann Sperl-Hillen; Denise E Bonds; Henry N Ginsberg
Journal:  Diabetes Care       Date:  2012-03-19       Impact factor: 19.112
View more
  2 in total

1.  The role of fibrates in chronic kidney disease and diabetes mellitus.

Authors:  Mark R Kahn; Michael J Robbins; Michael C Kim; Valentin Fuster
Journal:  Nat Rev Cardiol       Date:  2013-07-30       Impact factor: 32.419

Review 2.  Lipid mediators in diabetic nephropathy.

Authors:  Swayam Prakash Srivastava; Sen Shi; Daisuke Koya; Keizo Kanasaki
Journal:  Fibrogenesis Tissue Repair       Date:  2014-09-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.